All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.

The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

An expert panel hosted by

The Lymphoma Hub logo and the Multiple Myeloma Hub logo

Sequencing immune-based therapies in B-cell malignancies

with Ulric Jäger, Sagar Lonial, and Krina Patel

Saturday, June 15 | 18:00-19:30 CEST

Register now

This independent education activity is sponsored by Bristol Myers Squibb. All content is developed independently by the faculty. Funders are allowed no direct influence on the content of this activity.

  TRANSLATE

The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2024-06-06T16:12:35.000Z

How might AI be incorporated into the diagnosis and management of MM?

Jun 6, 2024
Share:
Learning objective: After reading this article, learners will be able to cite a new clinical development in multiple myeloma.

Bookmark this article

During the 5th European Myeloma Network Meeting, the Multiple Myeloma Hub was pleased to speak with Adrián Mosquera Orgueira, University of Santiago de Compostela, Santiago, ES. We asked, How might artificial intelligence (AI) be incorporated into the diagnosis and management of multiple myeloma?

How might AI be incorporated into the diagnosis and management of MM?

Adrián Mosquera Orgueira opens by emphasizing the importance of standardization of both diagnostic and prognostic tools in multiple myeloma (MM). He goes on to discuss how AI could be utilized to achieve this, particularly in more complex indicators such as measurable residual disease (MRD) and risk status. Mosquera Orgueira further highlights the predictive capability of AI to use patient profiles to determine which individuals will receive the most benefit from therapy, therefore helping tailor individualized treatment approaches.

Newsletter

Subscribe to get the best content related to multiple myeloma delivered to your inbox